Endpoint
Acute kidney injury incidence (any grade)
CAT:outcome/acute-kidney-injury-incidencereported in proportion1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| L-ascorbic acid | up | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
1 finding
L-ascorbic acid — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“A higher incidence of acute kidney injury (AKI) was found in the vitamin C-treated group (68.4%) than in the control group (35.0%), which was statistically significant (p=0.04), according to the Kidney Disease: Improving Global Outcomes (KDIGO) definition.”
Quoted verbatim from A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.. - Study
- RCT
- Dose
- 1500 mg intravenous bolus in 100 mL saline during the anhepatic phase, once
- Population
- Adults undergoing liver transplantation, single-centre pilot trial of 39 patients; a single 1500 mg intravenous ascorbic acid bolus before graft reperfusion versus 0.9% saline
A randomized trial of ascorbic acid for the prevention of post-reperfusion syndrome during liver transplantation.2025PMID:40719561Permalink
How it is measured
Proportion of patients developing acute kidney injury of any severity grade, staged by a named clinical criteria set (KDIGO, AKIN, RIFLE, or CTCAE). The criteria set and the clinical setting are recorded with each finding.
Sources cited
1 paper
- Subject
- acute kidney injury incidence (any grade)
- Findings
- 1
- Papers
- 1